



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA.
Email : hrm@gtbl.in.net
CIN No.: L24230GJ1981PLC004878

GTBL: CS: BSE-CORR/2024-25

26th July, 2024

The Manager,
Corporate Relationship Department,
BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.
Scrip Code – 506879

Dear Sir / Madam,

Sub: Outcome of Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Meeting Commencement time : 10: 30 A.M.
Meeting Conclusion Time : 1:55 P.M

Pursuant to Regulation 30 of the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Friday, 26th July, 2024, has inter-alia approved the Unaudited Standalone Financial Results for the Quarter ended 30th June, 2024 together with Limited Review Report issued by M/s. GMJ & Co., Chartered Accountants which are attached herewith.

- a) Board has approved and noted the resignation of Mr. Rahul D. Soni (ACS No. 61305) as the Company Secretary and Compliance Officer of the Company with effect from the closure of business hours of 02nd August, 2024.
- b) Appointment of Mr. Vineet G. Gawankar (ACS No. 55504) as Company Secretary & Compliance Officer in place of Mr. Rahul Soni with effect from 3rd September, 2024 based on the recommendation of the Nomination & Remuneration Committee.

The details in respect of a & b above as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFO/CMD/4/2015 dated 9th September, 2015 are given in Annexure "A".

The Board also approved the appointment of Mr. K. G. Ananthakrishnan (DIN: 00019325) as an Additional Independent Director of the Company w.e.f. 26th July, 2024 pursuant to the recommendation of Nomination & Remuneration Committee. are given in Annexure "B".

- c) The Company has fixed Friday, 9th August, 2024 as the "Record Date" for the purpose of determining the eligibility of shareholders for issuance of Bonus Shares



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA.
Email : hrm@gtbl.in.net
CIN No.: L24230GJ1981PLC004878

pursuant to Regulation 42 of The SEBI LODR, Regulations, 2015. The resolution for issuance of Equity Bonus shares has been already approved by the shareholders at the 43rd AGM held on 23rd July, 2024.

Kindly take the above on record.

Thanking you,

Yours faithfully,

For **GUJARAT THEMIS BIOSYN LIMITED**

Rahul Soni
Company Secretary & Compliance Officer



Encl: As above



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA.
Email : hrm@gtbl.in.net
CIN No.: L24230GJ1981PLC004878

Annexure - A

Sr. No	Particulars	Details
1	Reason for change viz. Resignation / Retirement, Appointment.	<p>Resignation:</p> <p>Mr. Rahul D. Soni has resigned as the Company Secretary and Compliance Officer of the Company with effect from the closure of business hours of 02nd August, 2024.</p> <p>Appointment:</p> <p>Appointment of Mr. Vineet G. Gawankar as the Company Secretary and Compliance Officer of the Company with effect from 03rd September, 2024.</p>
2	Date of appointment / resignation & term of Appointment	<p>The Board of Directors at its Meeting held on 26th July, 2024 based on the recommendation of Nomination and Remuneration Committee has appointed Mr. Vineet G. Gawankar as the Company Secretary and Compliance Officer of the Company w.e.f. 03rd September, 2024. consequent to resignation of Mr. Rahul Soni.</p>
3	Brief Profile (in case of appointment);	<p>Mr. Vineet Gawankar is qualified Company Secretary and also a Law and Commerce graduate from Mumbai university. He has over 7 years of experience in the area of Corporate Law, Corporate Governance, Legal and Compliance functions.</p>



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA.

Email : hrm@gtbl.in.net

CIN No.: L24230GJ1981PLC004878

		Prior to joining Gujarat Themis Biosyn Limited, he has worked with RPG Life Sciences, FDC Limited and Persistent Systems Limited.
O.4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA.
Email : hrm@gtbl.in.net
CIN No.: L24230GJ1981PLC004878

ANNEXURE-B

Mr. K. G. Ananthakrishnan (DIN: 00019325)

Sr. No.	Particulars	Remarks
1	Reason for change viz. appointment, Resignation, removal, death or otherwise	Appointment of Additional Non-Executive Independent Director w.e.f. July 26, 2024 pursuant to recommendation of Nomination and Remuneration Committee and approved by the Board of Directors at their meeting held on 26 th July, 2024.
2	Date of appointment and Term of appointment	Mr. K. G. Ananthakrishnan has been appointed as an Additional Non-Executive Independent Director (not liable to retire by rotation) of the Company w.e.f. 26 th July, 2024 for a period of 5 (five) years, subject to approval of the members of the Company.
3	Brief Profile	Mr. K. G. Ananthakrishnan is a Senior Management Executive with 40+ years of progressive leadership experience in the Pharmaceutical industry. Recognized in the industry for creating high performance organizations, driving success, delivering and sustaining revenue and profit growths in a highly competitive and growing pharmaceutical market. Led high performing teams, played key role in five merger & acquisitions, successfully established strategic partnerships, regarded as an industry thought leader, strategic thinker and out-of-the-box problem solver by senior executives. Served as Vice President - Organization of Pharmaceutical Producers of India (OPPI), Director General OPPI, Co-Chair (Pharma Committee) - Confederation of Indian Industry (CII). Invited as guest speaker by leading management institutions both in India and USA, Advisor and Mentor, Member of Pharma and Healthcare Board of IES MCRC, Former Member of "Think Tank on common scientific infrastructure for Hyderabad Pharma City" constituted by Government of Telangana, Non-Executive Chairman on the Board of Punjab National Bank and Independent Director - Suven Pharmaceuticals Ltd.



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA.

Email : hrm@gtbl.in.net

CIN No.: L24230GJ1981PLC004878

		Qualifications: Executive Development Program, Wharton Business School, USA, 2010 – 2011, Finance for Non-Finance Program, INSEAD, France, 2004; Masters in Marketing Management, Jamnalal Bajaj Institute OF Management Studies, Mumbai, 1995, Bachelor of Science. Osmania University, Hyderabad, 1976.
4	Disclosure of relationship between directors (In case of appointment of a Director)	There are no inter-se relations between Mr. K.G. Ananthakrishnan and the other members of the Board.

GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878


69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Financial Results for the Quarter ended June 30, 2024

(Amount in INR Lakhs)

Sr. No.	PARTICULARS	Quarter Ended		Year Ended	
		30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)
I	Income from operations	3,882.74	4,201.13	4,958.80	16,982.19
II	Other Income	52.43	101.83	107.47	436.57
III	Total Income (I+II)	3,935.17	4,302.97	5,066.27	17,418.76
IV	Expenditure				
	(a) Cost of raw material consumed	616.25	613.88	641.33	2,566.71
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of Finished Goods, Work-in-Progress and Stock in Trade	(12.11)	211.73	708.39	1,101.31
	(d) Employee benefits expense	319.63	297.91	207.75	1,021.48
	(e) Finance Cost	6.55	7.46	2.50	22.92
	(f) Depreciation and Amortisation expenses	114.80	92.48	74.90	353.59
	(g) Other Expenses				
	i) Stores and spares	174.49	180.36	93.53	492.73
	ii) Power	485.97	468.43	502.87	1,981.80
	iii) Fuel	122.92	134.31	145.45	545.28
	iv) Water	26.00	33.32	33.15	125.90
	v) Other expenditure	294.64	168.22	275.68	1,273.60
	Total Expenses	2,149.14	2,208.09	2,685.55	9,485.33
V	Profit/(Loss) before Exceptional Items and Tax (III-IV)	1,786.03	2,094.87	2,380.72	7,933.43
VI	Exceptional items	-	-	-	-
VII	Profit/(Loss) before Tax (V-VI)	1,786.03	2,094.87	2,380.72	7,933.43
VIII	Tax expenses				
	(a) Current Tax	457.14	467.94	598.98	1950.90
	(b) Deferred Tax	5.27	9.67	9.58	37.51
	(c) Income Tax of earlier years	-	28.70	-	28.70
IX	Net Profit/(Loss) after tax (VII-VIII)	1,323.62	1,588.56	1,772.16	5,916.32
X	Other Comprehensive Income				
	(a) Items that will not be reclassified to Profit or Loss				
	(i) remeasurement of defined benefit plans;	(1.07)	(8.32)	2.02	(4.27)
	(ii) Income Tax relating to items that will not be	0.27	2.13	(0.53)	1.07
	(b) Items that will be reclassified to Profit or Loss				
	(i) Income Tax relating to items that will be reclassified	-	-	-	-
XI	Total Comprehensive Income for the period (IX+X)	1,322.82	1,582.37	1,773.65	5,913.12
XII	Paid-up equity share capital	726.44	726.44	726.44	726.44
XIII	Other Equity				19,411.17
XIV	Earnings Per Share (Basic and Diluted)	1.82	2.19	2.44	8.14




GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Notes:

- 1 The financial results for the quarter ended June 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on July 26, 2024.
- 2 The Company operates only in one Business Segment i.e. manufacturing Bulk Drugs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".
- 3 The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 4 The figures for last quarter ended March 31, 2024 are the balancing figures between audited figures for the full financial year and unaudited published year-to-date figures upto the third quarter of the financial year.
- 5 Figures of previous periods/years' have been regrouped / rearranged, wherever considered necessary.

Place: Mumbai
Date : 26-07-2024



For GUJARAT THEMIS BIOSYN LIMITED

Dr. DINESH PATEL
Chairman
DIN : 00033273

Independent Auditor's Review Report on Quarterly Unaudited Financial Results and Year to Date Results Of Gujarat Themis Biosyn Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review report to
The Board of Directors
GUJARAT THEMIS BIOSYN LIMITED

We have reviewed the accompanying statement of unaudited financial results of **Gujarat Themis Biosyn Limited** ("the Company") for the quarter ended June 30, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulation") read with circular (Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019) issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, to the extent applicable.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of Companies Act 2013 read with rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For GMJ & Co
Chartered Accountants
FRN: 103429W



Amit Maheshwari

CA Amit Maheshwari

Partner

M. No.: 428706

UDIN: 244287 068KFN LG6968

Place : Mumbai

Date : July 26, 2024